AOD-9604

GRAS does not mean “FDA-approved peptide drug”

A 2013 safety paper reported that a qualified expert panel had concluded AOD-9604 was generally recognized as safe under specified intended food-use conditions. That is not the same as FDA approving a drug. It does not establish:

• efficacy for weight loss;
• safety of subcutaneous injection, nasal use, or transdermal use;
• safety of a compounded formulation;
• equivalence between a vendor’s vial and clinical-trial material; or
• authorization to market AOD-9604 as a treatment.

Why do participant totals differ?

Documents count different populations. The OPTIONS announcement reported 536 enrolled, the later pooled safety article described 502 obese adults, and the LAT8881 protocol reported 377 treated with active drug in METAOD006. These are not interchangeable denominators. MyPepFinder preserves the label attached to each number instead of presenting a single false total.

What happened at each studied dose or exposure level?

The early positive signal

A published obesity-pharmacotherapy review reported that participants receiving oral AOD-9604 1 mg/day lost an average 2.6 kg at 12 weeks, compared with 0.8 kg for placebo—a placebo-adjusted difference of about 1.8 kg. This finding came from the earlier development program and was the basis for further study.

The larger trial did not confirm efficacy

METAOD006/OPTIONS was the decisive obesity test: a randomized, double-blind, placebo-controlled, 24-week study of oral 0.25, 0.5, and 1 mg/day. Its primary endpoint was weight loss at 12 weeks. The study did not meet the primary endpoint, and the sponsor discontinued obesity development in 2007.

There are no completed Phase III obesity trials, no FDA-approved product, and no credible evidence that an injected compounded regimen produces better fat loss than the failed oral program.

Does AOD-9604 reduce belly fat or preserve muscle?

No reliable human trial has established targeted abdominal-fat reduction, “spot reduction,” or preferential preservation/building of lean mass. Claims that it “burns only fat” extrapolate from animal and laboratory findings. Human obesity trials measured overall outcomes; they did not validate a body-part-specific effect.

• Overall conclusion

  Early oral studies suggested modest weight loss and generally acceptable short-term tolerability, but the larger confirmatory obesity trial failed. Injectable compounded use is not supported by that evidence.

• Common adverse events

  Headache and gastrointestinal symptoms were commonly reported. The clearest dose-related pattern was more headache, diarrhea, flatulence, and abdominal/general symptoms at oral 54 mg over 7 days.

• IGF-1 and glucose

  Human oral trials did not find significant IGF-1 increases or statistically significant OGTT worsening versus placebo at 12 or 24 weeks — with duration and population limits.

• Compounded injection risk

  FDA says compounded AOD-9604 may pose immunogenicity and peptide-impurity risks and that available safety information is insufficient for proposed routes, especially repeated subcutaneous use.

Serious adverse events in METAOD005

Five serious events were reported during the 12-week study: breast cancer in the 5 mg arm, malignant melanoma in the 10 mg arm, and basal-cell carcinoma, lipoma, and squamous-cell carcinoma in the 20 mg arm. Investigators judged none possibly, probably, or definitely related to study medication. The pattern did not show a dose relationship, and no event occurred in the 30 mg arm. However, a small, short trial cannot exclude uncommon or delayed risks; “judged unrelated” is not equivalent to proof of no causal risk.

Laboratory, glucose, IGF-1, and antibody findings

FDA’s current compounding concern

FDA’s current position is more cautious than commercial “no side effects” claims. The agency says compounded AOD-9604 may pose immunogenicity risk for certain routes and raises concerns about aggregation, peptide impurities, and active-ingredient characterization. It has limited safety information for proposed compounded routes and cannot determine whether such products would harm humans. These concerns are particularly relevant to repeated subcutaneous use, which was not evaluated in the pivotal obesity trials.

Who was not adequately studied?

Evidence is insufficient for children, pregnant or breastfeeding people, older adults with multiple illnesses, people with active cancer, severe liver or kidney disease, uncontrolled diabetes, or those using AOD-9604 with GLP-1 drugs, GH, anabolic agents, or other research peptides.

Technical explanation

Mechanistic plausibility is not clinical effectiveness. A drug can alter lipolysis in a mouse or an isolated adipocyte and still fail to produce sustained weight loss in people—as the OPTIONS result illustrates.

Cartilage and osteoarthritis

AOD-9604 has been studied in rabbit cartilage-defect models, including work combining it with hyaluronic acid. Those studies suggested enhanced cartilage repair, but they are animal studies, not evidence that AOD-9604 heals human joints, reverses osteoarthritis, or improves human pain.

Neuropathic pain as LAT8881

The molecule was repurposed as LAT8881. NCT03865953 evaluated oral LAT8881 25 mg/day in a randomized, double-blind, placebo-controlled crossover Phase IIa study in postherpetic neuralgia or diabetic peripheral neuropathy. This program is scientifically distinct from obesity research. A pain-study dose should not be repurposed as a weight-loss dose.

METAOD001

Design: Randomized, double-blind, placebo-controlled, single IV dose escalation · Participants: 15 healthy men, BMI 24–30 · Dose: 25–400 µg/kg IV; somatropin positive control included · Main result: No clinically meaningful acute safety, glucose, or IGF-1 signal reported · Key limitation: Very small, male-only, single exposure; not a repeated subcutaneous trial

METAOD002

Design: Double-blind, placebo-controlled Latin-square study · Participants: 23 men with BMI ≥35 · Dose: 25, 50, or 100 µg/kg IV, single dose · Main result: Generally tolerated without meaningful glucose or IGF-1 changes

METAOD003

Design: Double-blind, placebo-controlled crossover · Participants: 17 men with obesity; 15 completed · Dose: Oral 9, 27, and 54 mg single doses with two-week washouts · Main result: Headache and gastrointestinal events were common across treatments; no consistent dose trend

METAOD004

Design: Randomized, double-blind, placebo-controlled multiple-dose study · Participants: 36 men with obesity · Dose: Oral 9, 27, or 54 mg/day, or placebo, for seven days · Main result: No serious adverse event; 54 mg was associated with more headache and gastrointestinal/general symptoms

METAOD005

Design: Randomized, double-blind, placebo-controlled Phase IIb dose-ranging study · Participants: 300 adults with BMI ≥35; 50 per arm · Duration: Two-week placebo run-in, then 12 weeks · Dose: Oral 1, 5, 10, 20, or 30 mg/day, or placebo · Main result: The widely cited 1 mg result was −2.6 kg versus −0.8 kg with placebo; no robust linear dose-response established

METAOD006 / OPTIONS

Design: Randomized, double-blind, placebo-controlled Phase IIb · Participants: 536 enrolled across 16 Australian sites; later sources use 502 for the study population and 377 for active-treated participants · Duration: 24 weeks; primary endpoint at week 12 · Dose: Oral 0.25, 0.5, or 1 mg/day, or placebo · Main result: Primary endpoint not met; obesity development discontinued in 2007

LAT-NP-001 / NCT03865953

Design: Phase IIa randomized, double-blind, placebo-controlled crossover · Participants: Adults with postherpetic neuralgia or diabetic peripheral neuropathy · Dose: Oral LAT8881 25 mg/day · Key limitation: Different indication; it cannot establish obesity efficacy or injectable safety